Sign in
4

Changes in Ownership

Adaptive Biotechnologies Corp Filed Acc 0001209191-20-051235

CEO and Chairman sold 50,040 shares at an average $45.76 ($2,290,077)

  • CEO and Chairman acquired 50,040 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
ROBINS CHAD M CEO and Chairman 2020-09-16 Option exercise +16,680 $0.33 $5,504 1,794,860 D: show line 1 in the form
ROBINS CHAD M CEO and Chairman 2020-09-16 Sale −6,180 $45.47 $281,005 1,788,680 D: show line 2 in the form
ROBINS CHAD M CEO and Chairman 2020-09-16 Sale −5,000 $46.45 $232,250 1,738,680 D: show line 3 in the form
ROBINS CHAD M CEO and Chairman 2020-09-16 Sale −5,100 $47.46 $242,046 1,778,580 D: show line 4 in the form
ROBINS CHAD M CEO and Chairman 2020-09-16 Sale −400 $48.26 $19,304 1,778,180 D: show line 5 in the form
ROBINS CHAD M CEO and Chairman 2020-09-17 Option exercise +16,680 $0.33 $5,504 1,794,860 D: show line 6 in the form
ROBINS CHAD M CEO and Chairman 2020-09-17 Sale −2,600 $44.48 $115,648 1,792,260 D: show line 7 in the form
ROBINS CHAD M CEO and Chairman 2020-09-17 Sale −14,080 $45.26 $637,261 1,778,180 D: show line 8 in the form
Open-market sales · 50,040 sh · avg $45.76 · $2,290,077

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
ROBINS CHAD M CEO and Chairman 2020-09-16 Option exercise · Stock Option (Right to Buy) −16,680 228,000 D: show line 12 in the form
ROBINS CHAD M CEO and Chairman 2020-09-17 Option exercise · Stock Option (Right to Buy) −16,680 211,320 D: show line 13 in the form
ROBINS CHAD M CEO and Chairman 2020-09-18 Option exercise · Stock Option (Right to Buy) −16,680 194,640 D: show line 14 in the form
Loading xslF345X03/doc4.xml…